Paradoxical effect of reagents for sulfhydryl and disulfide groups on human sperm capacitation and superoxide production.
Spermatozoa must undergo capacitation prior to fertilization. In humans, this process appears regulated by oxidoreduction reactions. We investigated the possibility that these reactions involved the sulfhydryl-disulfide pair, which offers a reversible regulation of cellular processes. The effects of reagents targeted for sulfhydryl and disulfide groups on human sperm capacitation, superoxide (O2-.) generation and protein tyrosine phosphorylation were evaluated. The sulfhydryl targeted agents, phenylarsine oxide (PAO), diamide, dithiopyridine (DTP), N-ethylmaleimide (NEM), maleimidylpropionyl biocytin (MPB), p-chloromercuribenzoic acid (PCMB), and bromobimane analogs (mBBr and qBBr) triggered sperm capacitation to levels comparable to those observed with a biological inducer, fetal cord serum ultrafiltrate (FCSu). Capacitation induced by NEM, MPB, PCMB, and PAO was prevented by superoxide dismutase (SOD) and associated with an increased sperm production of O2-.. However, SOD did not affect the increase in protein tyrosine phosphorylation of spermatozoa treated with NEM, PAO, or MPB. Disulfide reductants, dithiothreitol (DTT), thioredoxin (TRX), glutathione (GSH), tris-(2-carboxyethyl) phosphine (TCEP), and tris-(2-cyanoethyl) phosphine (TCP) partially to totally inhibited FCSu-induced sperm capacitation and O2-. production. TCEP, DTT, and TRX decreased the capacitation-associated tyrosine phosphorylation of sperm proteins. The strong time-dependent increase of sperm membrane sulfhydryl groups exposed to the extracellular space occurring during the first hour of capacitation could indicate an important rearrangement of sulfhydryl carrying proteins during the initiation of capacitation. Therefore, protein sulfhydryl-disulfide status may be important for the regulation of human sperm capacitation and the mechanisms involved may be complex and multifactorial.
de Lamirande
E
E
Urology Research Laboratory, Royal Victoria Hospital, Montréal, Québec, Canada.
Gagnon
C
C
D004220:Disulfides / Q000737:chemistry* / Q000378:metabolism; D004229:Dithiothreitol / Q000494:pharmacology; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives / Q000737:chemistry; D008297:Male; D008301:Maleimides / Q000737:chemistry; D010084:Oxidation-Reduction; D013075:Sperm Capacitation / Q000187:drug effects*; D013094:Spermatozoa / Q000187:drug effects* / Q000502:physiology; D013438:Sulfhydryl Compounds / Q000737:chemistry* / Q000378:metabolism; D013439:Sulfhydryl Reagents / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism*
D004220:Disulfides; D008301:Maleimides; D013438:Sulfhydryl Compounds; D013439:Sulfhydryl Reagents; D013481:Superoxides; C047272:3-(N-maleimidopropionyl)biocytin; D013482:Superoxide Dismutase; D008239:Lysine; D004229:Dithiothreitol